Study of Carisbamate in Adult and Pediatric Subjects with Lennox-Gastaut Syndrome

Study of Carisbamate in Adult and Pediatric Subjects with Lennox-Gastaut Syndrome
Recruiting
18 years - 99 years
All
Phase 1
3 participants needed
1 Location

Brief description of study

The purpose of this study is to learn more about the use of carisbamate (the Study Drug) for the treatment of LGS in children and adults. The Study Drug has not yet been approved by the FDA - it is an experimental treatment. The Study Drug belongs to the anti-convulsant class of drugs. Other drugs in this class have been approved to treat LGS

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: LGS,Lennox-Gastaut Syndrome,seizures,intractable epilepsy,drop attacks
  • Age: 18 years - 99 years
  • Gender: All


Updated on 19 Feb 2024. Study ID: 832308

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.